Alnylam and Regeneron to Advance NASH ALN-HSD Asset

Alnylam and Regeneron announced initial Part B data from the ALN-HSD Ph1 NASH study (view CT.gov record) and disclosed plans to initiate Ph2 development in late 2022. Recall, during its November 2021 R&D webinar, Alnylam highlighted 14-week HSD17B13 knockdown results from Part A of the ALN-HSD Ph1 study (previous FENIX insight). Below, FENIX provides context and insight on the latest ALN-HSD data readout.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.